EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers

Mikael Sunnåker, Chandrali Bhattacharya, Karin Nelander, Malin Aurell, Maria Heijer, Anna Collén, David Han, Julie Holden, Monika Trebski, Pavlo Garkaviy, Hans Ericsson

Clinical Drug Investigation · 2024-11 · 44 (11) · 863-874

DOI: 10.1007/s40261-024-01402-x ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Drug Investigation, online erschienen am 04.11.2024. Verfasst von Mikael Sunnåker und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Swed…. Hauptthemen laut MEDLINE: Enzyme Inhibitors, Peroxidase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Mitiperstat (AZD4831) is a novel irreversible oral myeloperoxidase inhibitor in clinical development for heart failure with preserved ejection fraction, metabolic dysfunction-associated steatohepatitis and chronic obstructive pulmonary disease. This study evaluated the pharmacokinetics, safety and tolerability of multiple ascending doses of mitiperstat in healthy male Japanese and Chinese volunteers. METHODS: Three cohorts of eight Japanese participants were randomized to receive once-daily oral doses of mitiperstat 2.5, 5 or 10 mg or matching placebo for 10 days (six receiving mitiperstat and two receiving placebo, per cohort). One cohort of eight Chinese participants was randomized to receive mitiperstat 5 mg or matching placebo for 10 days (six receiving mitiperstat and two receiving placebo). RESULTS: Mitiperstat was rapidly absorbed, with a time to maximum plasma concentration of 1-2 h. Exposure was dose proportional over the investigated dose range, as assessed by area under the concentration-time curve and maximum and trough plasma concentrations. Steady state was reached within 10 days, and accumulation was observed, consistent with the observed long elimination half-life of mitiperstat (50.2-57.8 h). Except for a few events of maculopapular rash, mitiperstat up to 5 mg was well tolerated in participants of Japanese or Chinese origin. CONCLUSIONS: The pharmacokinetics of mitiperstat were similar among Japanese and Chinese participants. These characteristics were similar to those in a previous multiple ascending-dose study in healthy primarily white and Black/African American volunteers. Therefore, the pharmacokinetics of mitiperstat do not affect dosing regimens in these different populations. TRIAL REGISTRATION: NCT04232345 (03/01/2020).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enzyme InhibitorsPeroxidaseAdultHumansMaleMiddle AgedYoung AdultChinaDose-Response Relationship, DrugDouble-Blind MethodEast Asian PeopleHealthy VolunteersJapan

Substanzen

Enzyme InhibitorsPeroxidase

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden. mikael.sunnaker1@astrazeneca.com.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, MD, USA.
  • CVRM Biometrics, Late CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Early Clinical Development, Research and Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Projects, Research and Early Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Förderung

  • AstraZeneca

Zitieren

APA

Sunnåker, M., Bhattacharya, C., Nelander, K., Aurell, M., Heijer, M., Collén, A., Han, D., Holden, J., Trebski, M., Garkaviy, P., & Ericsson, H. (2024). Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers. Clinical Drug Investigation, 44(11), 863-874. https://doi.org/10.1007/s40261-024-01402-x

Vancouver

Sunnåker M, Bhattacharya C, Nelander K, Aurell M, Heijer M, Collén A, et al. Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers. Clinical Drug Investigation. 2024;44(11):863-874. doi:10.1007/s40261-024-01402-x

BibTeX
@article{Sunnker2024,
  author = {Sunnåker, Mikael and Bhattacharya, Chandrali and Nelander, Karin and Aurell, Malin and Heijer, Maria and Collén, Anna and Han, David and Holden, Julie and Trebski, Monika and Garkaviy, Pavlo and Ericsson, Hans},
  title = {Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers},
  journal = {Clinical Drug Investigation},
  year = {2024},
  volume = {44},
  number = {11},
  pages = {863--874},
  doi = {10.1007/s40261-024-01402-x}
}
Kostenlos starten →